Dopamine agonist treatment in early Parkinson’s disease
Due to insufficient antiparkinsonian efficacy, dopamine agonists alone do not seem to be useful as the primary treatment for the majority of parkinsonian patients, despite the fact that they produce only few fluctuations in disability. Early combination of dopamine agonist and a low dose of levodopa seems not only to improve parkinsonian disability, but also to inhibit the development of fluctuations in disability, especially end-of-dose disturbances and dyskinesias. Thus it appears advisable that the management of parkinsonian patients should begin in the early phase of the disease with this kind of combination.
KeywordsDopamine Receptor Dopamine Agonist Dopamine Neuron Striatal Dopamine Parkinsonian Patient
Unable to display preview. Download preview PDF.
- Birkmayer W (1976) Medical treatment of Parkinson’s disease: General review, past and present. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basle, pp 407–423Google Scholar
- Carlsson A (1983) Are “on-off” effects during chronic L-Dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm 19: 153–161Google Scholar
- Gessa GL (1988) Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence. J Neural Transm [Suppl] 27: 201–210Google Scholar
- Leenders KL, Herold S, Palmer AJ, Turton D, Quinn N, Jones T, Frackowiak RSJ, Marsden CD (1985) Human cerebral dopamine system measured in vivo using PET. J Cerebral Blood Flow Metab 5 /1: 157–158Google Scholar
- Ogawa N, Yamawaki Y, Kuroda H, Takayama H, Ota Z (1984) Differences in the effects of levodopa and bromocriptine on rat striatal dopamine receptors. Neurosciences 10: 259–266Google Scholar
- Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 431–442Google Scholar
- Rinne UK (1986) Dopamine agonists as primary treatment in Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology. Raven Press, New York, pp 519–523Google Scholar
- Rinne UK, Sonninen V, Siirtola T (1976) Long-term treatment of parkinsonism with L-Dopa and decarboxylase inhibitor: A clinical and biochemical approach. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basle, pp 555–565Google Scholar
- Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease: Mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basle, pp 435–443Google Scholar